SCHEMBL220455

SCHEMBL220455

O=C(CBr)c1n[nH]c2ccccc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 6/20 0.65
WNT3A P56704 6/20 0.65
KDM4E B2RXH2 5/20 0.57
YTHDC1 Q96MU7 1/20 0.57
STAT3 P40763 1/20 0.57
HIF1A Q16665 1/20 0.57
CCNA2 P20248 1/20 0.54
CDK2 P24941 1/20 0.54
FLT3 P36888 1/20 0.54
CCNA1 P78396 1/20 0.54
NPC1 O15118 5/20 0.51
RAB9A P51151 4/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
IDO1 P14902 1/20 0.51
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.50
MAPT P10636 1/20 0.50
NFKB1 P19838 1/20 0.50
HTT P42858 1/20 0.50
NFKB2 Q00653 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31295133 1.00 CTNNB1 (0.65) CTNNB1WNT3AKDM4EYTHDC1STAT3
SCHEMBL18967655 0.83 CTNNB1 (0.65) CTNNB1WNT3AKDM4EYTHDC1STAT3
SCHEMBL7668372 0.80 KDM4E (0.66) CTNNB1WNT3AKDM4EYTHDC1STAT3
SCHEMBL31148407 0.80 KDM4E (0.66) CTNNB1WNT3AKDM4EYTHDC1STAT3
SCHEMBL15968795 0.79 CTNNB1 (1.00) CTNNB1WNT3AKDM4EYTHDC1STAT3
SCHEMBL5353834 0.78 FLT3 (0.65) CTNNB1WNT3AKDM4EYTHDC1STAT3
SCHEMBL42245 0.78 FLT3 (0.65) CTNNB1WNT3AKDM4EYTHDC1STAT3
SCHEMBL29444537 0.78 FLT3 (0.65) CTNNB1WNT3AKDM4EYTHDC1STAT3
SCHEMBL17423779 0.78 GSK3B (0.49) CTNNB1WNT3ARAB9AIDO1
SCHEMBL29687771 0.78 KDM4E (0.71) KDM4ESTAT3HIF1ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2262804-B1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO[L,2- A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-12-03 EP disclosed
US-8598166-B2 Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI (FR) 2013-12-03 US disclosed
US-20120053202-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2012-03-01 US disclosed
US-8088765-B2 Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2012-01-03 US disclosed
US-20110065700-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US disclosed
US-7893280-B2 2,4-disubstituted thiazolyl derivatives JANSSEN PHARMACEUTICA NV (BE) 2011-02-22 US disclosed
EP-2262804-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO[L,2- A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-aventis (FR) 2010-12-22 EP disclosed
WO-2009144392-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO[L,2- Α] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-12-03 WO disclosed
EP-1261607-B1 2,4-DISUBSTITUTED THIAZOLYL DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2008-11-12 EP disclosed
US-20060211704-A1 2,4-Disubstituted thiazolyl derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2006-09-21 US disclosed
US-7105550-B2 2,4-disubstituted thiazolyl derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2006-09-12 US disclosed
US-20030203897-A1 2,4-Disubstituted thiazolyl derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2003-10-30 US disclosed
EP-1261607-A1 2,4-DISUBSTITUTED THIAZOLYL DERIVATIVES Janssen Pharmaceutica N.V. (BE) 2002-12-04 EP disclosed
WO-2001064674-A1 2,4-DISUBSTITUTED THIAZOLYL DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2001-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211704-A1 2,4-Disubstituted thiazolyl derivatives IL4, PTGER4, PTGER3 CTNNB1 2163/4885WNT3A 1195/4885KDM4E 2474/4885
US-20030203897-A1 2,4-Disubstituted thiazolyl derivatives IL4, PTGER4, PTGER1 CTNNB1 1981/4885WNT3A 2060/4885KDM4E 2524/4885
US-20110065700-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF CYP4X1, HAX1, JAK2 CTNNB1 3642/4885WNT3A 3848/4885KDM4E 1360/4885
US-20120053202-A1 POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF CYP4X1, HAX1, JAK2 CTNNB1 3642/4885WNT3A 3848/4885KDM4E 1360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.